


<b>ISSUE DATE</b>  November 8, 2022	<b>EFFECTIVE DATE</b>  January 9, 2023	<b>NUMBER</b>  *See below
<b>SUBJECT</b>  Prior Authorization of Dupixent (dupilumab) – Pharmacy Services	<b>BY</b>   Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs	

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISE to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISE-Enrollment.aspx>.

**PURPOSE:**

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Dupixent (dupilumab) submitted for prior authorization.

**SCOPE:**

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program. The guidelines to determine the medical necessity of Dupixent (dupilumab) will be utilized in the fee-for-service and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should address any questions related to the prior authorization of Dupixent (dupilumab) to the appropriate managed care organization.

**BACKGROUND:**

The Department of Human Services’ (Department) Pharmacy and Therapeutics (P&T)

*01-22-58	09-22-57	27-22-45	33-22-55
02-22-42	11-22-42	30-22-48	
03-22-41	14-22-42	31-22-61	
08-22-66	24-22-50	32-22-42	

**COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:**

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at <https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

Committee reviews published peer-reviewed medical literature and recommends the following:

- Preferred or non-preferred status for new drugs and products in therapeutic classes already included in the Preferred Drug List (PDL).
- Changes in the status of drugs and products on the PDL from preferred to non-preferred and non-preferred to preferred.
- New quantity limits.
- Therapeutic classes of drugs and products to be added to or deleted from the PDL.
- New guidelines or revisions to existing guidelines to evaluate the medical necessity of prescriptions submitted for prior authorization.

### **DISCUSSION:**

During the September 14, 2022, meeting, the P&T Committee recommended the following revisions to the guidelines to determine medical necessity of Dupixent (dupilumab):

- Addition of a guideline that the beneficiary is age-appropriate according to U.S. Food and Drug Administration-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature.
- Addition of a guideline that Dupixent is prescribed by or in consultation with an appropriate specialist.
- Revision of the guidelines for the treatment of atopic dermatitis to consider the length of time for trials of topical corticosteroids and topical calcineurin inhibitors.
- Addition of a guideline for the treatment of eosinophilic esophagitis.
- Addition of a guideline that for all other diagnoses, the beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines.
- Revision of the guideline for requests for renewals of prior authorizations related to improvement in disease severity.

The revisions to the guidelines to determine medical necessity of prescriptions for Dupixent (dupilumab) submitted for prior authorization, as recommended by the P&T Committee, were subject to public review and comment and subsequently approved for implementation by the Department.

### **PROCEDURE:**

The procedures for prescribers to request prior authorization of Dupixent (dupilumab) are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Dupixent [dupilumab]) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs and products that require prior authorization.

**ATTACHMENTS:**

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

**RESOURCES:**

Prior Authorization of Pharmaceutical Services Handbook – SECTION I  
Pharmacy Prior Authorization General Requirements

<https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Pharmacy-Prior-Authorization-General-Requirements.aspx>

Prior Authorization of Pharmaceutical Services Handbook – SECTION II  
Pharmacy Prior Authorization Guidelines

<https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Clinical-Guidelines.aspx>

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

**I. Requirements for Prior Authorization of Dupixent (dupilumab)**

**A. Prescriptions That Require Prior Authorization**

All prescriptions for Dupixent (dupilumab) must be prior authorized.

**B. Review of Documentation for Medical Necessity**

In evaluating a request for prior authorization of a prescription for Dupixent (dupilumab), the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
2. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Is prescribed Dupixent (dupilumab) by or in consultation with an appropriate specialist (e.g., pulmonologist, allergist, immunologist, dermatologist, hematologist/oncologist, rheumatologist, etc.); **AND**
5. If currently using a different Monoclonal Antibody (MAB) – Anti-IL, Anti-IgE, Anti-TSLP, will discontinue the other MAB – Anti-IL, Anti-IgE, Anti-TSLP prior to starting Dupixent (dupilumab); **AND**
6. For treatment of moderate to severe chronic atopic dermatitis, has a history of therapeutic failure of at least **two** of the following OR a contraindication or an intolerance to **all** of the following:
  - a. **One** of the following:
    - i. For treatment of the face, skin folds, or other critical areas, a 4-week trial of a low-potency topical corticosteroid
    - ii. For treatment of other areas, a 4-week trial of a medium-potency or higher topical corticosteroid,
  - b. An 8-week trial of a topical calcineurin inhibitor,
  - c. Phototherapy in accordance with current consensus guidelines,
  - d. Systemic immunosuppressives in accordance with current consensus guidelines (e.g.,

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

cyclosporine, azathioprine, methotrexate, mycophenolate mofetil);

**AND**

7. For a diagnosis of asthma, **all** of the following:
  - a. Has asthma severity consistent with the FDA-approved indication for Dupixent (dupilumab) despite maximal therapeutic doses of or intolerance or contraindication to asthma controller medications based on current national treatment guidelines for the diagnosis and management of asthma,
  - b. **One** of the following:
    - i. Has absolute blood eosinophil count  $\geq 150$  cells/microL
    - ii. Is dependent on oral corticosteroids,
  - c. Will use Dupixent (dupilumab) in addition to standard asthma controller medications as recommended by current national treatment guidelines;

**AND**

8. For a diagnosis of eosinophilic esophagitis, has a history of therapeutic failure of or a contraindication or an intolerance to a proton pump inhibitor; **AND**
9. For all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines; **AND**
10. If a prescription Dupixent (dupilumab) is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. See Quantity Limits List: <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR DUPIXENT (DUPILUMAB): The determination of medical necessity of a request for renewal of a prior authorization for Dupixent (dupilumab) that was previously approved will take into account whether the beneficiary:

1. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

recognized compendia, or peer-reviewed medical literature; **AND**

2. Is prescribed Dupixent (dupilumab) by or in consultation with an appropriate specialist (e.g., pulmonologist, allergist, immunologist, dermatologist, hematologist/oncologist, rheumatologist, etc.); **AND**
3. Has documented evidence of improvement in disease severity; **AND**
4. For a diagnosis of asthma, **both** of the following:
  - a. **One** of the following:
    - i. Has documented measurable evidence of improvement in the severity of the asthma condition
    - ii. Has reduction of oral corticosteroid dose while maintaining asthma control
  - b. Continues to use Dupixent (dupilumab) in addition to standard asthma controller medications as recommended by current national treatment guidelines;

**AND**

5. If a prescription Dupixent (dupilumab) is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. See Quantity Limits List: <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

**C. Clinical Review Process**

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for Dupixent (dupilumab). If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

**D. References**

1. Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.: June 2022.

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

2. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375:2335-48.
3. Weston W, Howe W. Treatment of atopic dermatitis (eczema). Dellavalle RP, Levy ML, Fowler J, Corona R, eds. Waltham, MA: UpToDate. Updated April 15, 2021. Accessed May 5, 2021.
4. Berger, TG. Evaluation and management of severe refractory atopic dermatitis (eczema) in adults. Fowler J, Levy ML, Dellavalle RP, Corona R, eds. Waltham, MA: UpToDate. Updated March 18, 2021. Accessed May 5, 2021.
5. Spergel JM, Lio PA. Management of severe atopic dermatitis (eczema) in children. Dellavalle RP, Levy ML, Fowler J, Corona R, eds. Waltham, MA: UpToDate. Updated August 5, 2020. Accessed May 5, 2021.
6. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-32.
7. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2):327-49.
8. Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. *J Allergy Clin Immunol Pract*. 2017;5(6):1519-1531.
9. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *J Eur Acad Dermatol Venereol*. 2020;34(12):2717-2744.
10. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatment for patients with atopic dermatitis – a systemic review and network meta-analysis. *JAMA Dermatol*. 2020;156(6):659-667.
11. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. *Allergy*. 2021;76(4):1053-1076.
12. Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. *Cochrane Database Syst Rev*. 2020;9:CD013206. Published 2020 Sep 14.
13. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120:10-22.
14. Wenzel S. Treatment of severe asthma in adolescents and adults. Bochner BS, Hollingsworth H, eds. Waltham, MA: UpToDate. Updated March 23, 2022. Accessed April 18, 2022.
15. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2022. <http://www.ginasthma.org>. Accessed April 18, 2022.
16. Global Initiative for Asthma. Difficult-to-treat & severe asthma in adolescents and adult patients – diagnosis and management, April 2019. <http://www.ginasthma.org>. Accessed May 3, 2021.
17. U.S. Department of Health, National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma – Full Report 2007. [https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln\\_1.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf). Published October 2007. Accessed April 18, 2022.
18. U.S. Department of Health, National Institutes of Health, National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Published December 2020.
19. Rosenfeld RM, Piccirillo JF, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2S):S1–S39.
20. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. *Allergy*. 2019;00:1–8.
21. Hamilos DL, Holbrook EH. Chronic rhinosinusitis: management. Corren J, Deschler DG, Feldweg AM, eds. Waltham, MA: UpToDate. Updated February 17, 2021. Accessed May 5, 2021.